Want to get involved in celiac disease research? It’s time to take action. 

The TEV-CeD Study is a phase 1b clinical trial testing the investigational medication TEV-53408 for the treatment of celiac disease.   

TEV-53408 is an antibody designed to block interleukin-15 with the goal of preventing intestinal damage and symptoms that occur when people with celiac disease ingest gluten.   

This research study aims to find out if a single injection of the study medication is safe and well-tolerated in adults with celiac disease compared to a placebo, before and after eating snacks that contain gluten.   

Compensation for time and travel may be available.  


  • 18-70 years old   
  • Biopsy-confirmed celiac disease   
  • On a gluten-free diet  


  • Wyoming, MI

Potential Benefits of Participation: 

  • Opportunity to access a cutting-edge investigational treatment   
  • Receive expert study-related medical care at no cost   
  • Play a key role in making better treatments for celiac disease a reality  

Learn more: tevstudy.celiac.org

Find out if you may qualify: iqualify.celiac.org 


About the Sponsor 

Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. They are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. Learn more at www.tevapharm.com.  

Join the TEV-CeD Study for Celiac Disease